# Arcturus Meiji Investment Details

> Arcturus Therapeutics secures $50m Meiji investment at 80% premium for mRNA tech.
- Title: Arcturus Meiji Investment Details · Pulse 2.0 | Shortify
- Summary: Arcturus Therapeutics secures $50m Meiji investment at 80% premium for mRNA tech.
- Keywords: arcturus therapeutics, meiji seika pharma, mrna, cystic fibrosis, ornithine transcarbamylase deficiency, lunar 2.0 delivery platform, pandemic preparedness, Pulse 2.0
- URL: https://shortify.news/Pulse_2.0/arcturus-meiji-investment-details
- Source: Pulse 2.0 — https://pulse2.com/arcturus-therapeutics-secures-50-million-meiji-investment-at-80-premium
- Author: Amit Chowdhry
- Published: 2026-11-17T21:20:45+00:00
- Read time: 1 min
- Topics: arcturus therapeutics, meiji seika pharma, mrna, cystic fibrosis, ornithine transcarbamylase deficiency, lunar 2.0 delivery platform, pandemic preparedness, startups, business
## Investment Terms
Meiji purchases Arcturus securities at $20.27 per share, an 80% premium, representing 7.9% of shares.
## Technology License
Arcturus licenses ARCT-154 technology for an undisclosed therapeutic area.
## Pandemic Partnership
Meiji and Arcturus agree to potential pandemic preparedness collaboration in Japan.
## Key takeaway

Arcturus Therapeutics received $50 million from Meiji Seika Pharma at 80% premium for its mRNA platform, accelerating cystic fibrosis and ornithine transcarbamylase deficiency treatments.

---

Summary: Shortify — https://shortify.news/Pulse_2.0/arcturus-meiji-investment-details
Reporting: Pulse 2.0 — https://pulse2.com/arcturus-therapeutics-secures-50-million-meiji-investment-at-80-premium

When you use this summary, link the Shortify URL for the summary and credit the reporting to its newsroom.